Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research
June 24th 2025Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.
Watch
IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C
June 23rd 2025Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.
Read More
ADA 2025: Ready-to-Use Glucagon Empowers Diabetes Patient Safety
Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.
Watch
Psychedelic Group Therapy Expands From Cancer Care to Treat PTSD in Active Duty Military
June 23rd 2025Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military post-traumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.
Watch
ADA 2025: Breaking Barriers in Glucagon Prescription
Experts discuss the low prescription rates of ready-to-use glucagon for individuals with diabetes.
Watch
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.
Read More